News | Proton Therapy | October 23, 2018

Varian Introduces New ProBeam 360° Proton Therapy System

New single-room system features 30 percent smaller footprint than Varian’s previous-generation proton therapy system

Varian Introduces New ProBeam 360° Proton Therapy System

October 23, 2018 — Varian announced its new single-room proton therapy system, ProBeam 360°, at the 2018 American Society of Radiation Oncology (ASTRO) annual meeting, Oct. 21-24 in San Antonio, Texas. With a 30 percent smaller footprint than the previous system, ProBeam 360° offers uncompromised clinical capabilities, according to Varian, while reducing vault construction costs by approximately 25 percent. The new system has a 360-degree rotating gantry, a powerful particle accelerator, iterative cone-beam computed tomography (CBCT) imaging and high-definition pencil-beam scanning technology. The system can also provide clinicians a viable path to potential next-generation treatments such as Flash therapy.

The 360-degree rotating gantry of ProBeam 360° enables efficient intensity modulated proton therapy (IMPT), and faster treatment times by minimizing patient repositioning and re-imaging, and allowing high-quality CBCT imaging from almost any angle. RapidScan technology, available on the ProBeam 360°, simplifies the process of motion management by delivering each field in a single breath-hold. This capability increases the number of patients who can comply with breath-hold treatments like lung SBRT.

Additionally, Varian's high-definition pencil-beam scanning technology gives clinicians the ability to deliver the dose precisely within the contours of the tumor to minimize dose to healthy tissue. When combined with iterative CBCT, the ProBeam 360° system enables adaptive precision radiation therapy during the course of treatment, helping to make it an even more precise form of proton therapy.

For more information: www.varian.com

Related Content

Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes

Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes. The metallic-based nanoparticles show up on CT scans so it can be used as a permanent fiduciary marker to track tumor response. The images show the initial tumor and enhancement areas due to the nanoparticles and the resulting outcomes following treatment. Photo by Dave Fornell

Feature | Radiation Oncology | January 30, 2019 | By Dave Fornell
Artificial intelligence (AI) has been the hot topic discussed at all trade shows, and the...
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof